Shopping Cart 0
Cart Subtotal
AED 0

Hidradenitis Suppurativa - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020

Details

Hidradenitis Suppurativa-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa-Pipeline Review, H1 2019, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 1, 5 and 3 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).

- The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Hidradenitis Suppurativa-Overview

Hidradenitis Suppurativa-Therapeutics Development

Hidradenitis Suppurativa-Therapeutics Assessment

Hidradenitis Suppurativa-Companies Involved in Therapeutics Development

Hidradenitis Suppurativa-Drug Profiles

Hidradenitis Suppurativa-Dormant Projects

Hidradenitis Suppurativa-Discontinued Products

Hidradenitis Suppurativa-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Hidradenitis Suppurativa, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Hidradenitis Suppurativa, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hidradenitis Suppurativa-Pipeline by AbbVie Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by Aclaris Therapeutics Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by Alvotech Iceland, H1 2019

Hidradenitis Suppurativa-Pipeline by Celgene Corp, H1 2019

Hidradenitis Suppurativa-Pipeline by ChemoCentryx Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by Fresenius SE & Co KGaA, H1 2019

Hidradenitis Suppurativa-Pipeline by Immunwork Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by Incyte Corp, H1 2019

Hidradenitis Suppurativa-Pipeline by InflaRx NV, H1 2019

Hidradenitis Suppurativa-Pipeline by Innovation Pharmaceuticals Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by InSight Biopharmaceuticals Ltd, H1 2019

Hidradenitis Suppurativa-Pipeline by Johnson & Johnson, H1 2019

Hidradenitis Suppurativa-Pipeline by Novartis AG, H1 2019

Hidradenitis Suppurativa-Pipeline by UCB SA, H1 2019

Hidradenitis Suppurativa-Pipeline by XBiotech Inc, H1 2019

Hidradenitis Suppurativa-Dormant Projects, H1 2019

Hidradenitis Suppurativa-Discontinued Products, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Hidradenitis Suppurativa Therapeutic Products under Development, Key Players in Hidradenitis Suppurativa Therapeutics, Hidradenitis Suppurativa Pipeline Overview, Hidradenitis Suppurativa Pipeline, Hidradenitis Suppurativa Pipeline Assessment


Companies

AbbVie Inc

Aclaris Therapeutics Inc

Alvotech Iceland

Celgene Corp

ChemoCentryx Inc

Fresenius SE & Co KGaA

Immunwork Inc

Incyte Corp

InflaRx NV

Innovation Pharmaceuticals Inc

InSight Biopharmaceuticals Ltd

Johnson & Johnson

Novartis AG

UCB SA

XBiotech Inc

Company Profile

Company Profile Title

Hidradenitis Suppurativa-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa-Pipeline Review, H1 2019, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 1, 5 and 3 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).

- The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents

Introduction

Hidradenitis Suppurativa-Overview

Hidradenitis Suppurativa-Therapeutics Development

Hidradenitis Suppurativa-Therapeutics Assessment

Hidradenitis Suppurativa-Companies Involved in Therapeutics Development

Hidradenitis Suppurativa-Drug Profiles

Hidradenitis Suppurativa-Dormant Projects

Hidradenitis Suppurativa-Discontinued Products

Hidradenitis Suppurativa-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Hidradenitis Suppurativa, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Hidradenitis Suppurativa, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hidradenitis Suppurativa-Pipeline by AbbVie Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by Aclaris Therapeutics Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by Alvotech Iceland, H1 2019

Hidradenitis Suppurativa-Pipeline by Celgene Corp, H1 2019

Hidradenitis Suppurativa-Pipeline by ChemoCentryx Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by Fresenius SE & Co KGaA, H1 2019

Hidradenitis Suppurativa-Pipeline by Immunwork Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by Incyte Corp, H1 2019

Hidradenitis Suppurativa-Pipeline by InflaRx NV, H1 2019

Hidradenitis Suppurativa-Pipeline by Innovation Pharmaceuticals Inc, H1 2019

Hidradenitis Suppurativa-Pipeline by InSight Biopharmaceuticals Ltd, H1 2019

Hidradenitis Suppurativa-Pipeline by Johnson & Johnson, H1 2019

Hidradenitis Suppurativa-Pipeline by Novartis AG, H1 2019

Hidradenitis Suppurativa-Pipeline by UCB SA, H1 2019

Hidradenitis Suppurativa-Pipeline by XBiotech Inc, H1 2019

Hidradenitis Suppurativa-Dormant Projects, H1 2019

Hidradenitis Suppurativa-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Hidradenitis Suppurativa Therapeutic Products under Development, Key Players in Hidradenitis Suppurativa Therapeutics, Hidradenitis Suppurativa Pipeline Overview, Hidradenitis Suppurativa Pipeline, Hidradenitis Suppurativa Pipeline Assessment


Companies

AbbVie Inc

Aclaris Therapeutics Inc

Alvotech Iceland

Celgene Corp

ChemoCentryx Inc

Fresenius SE & Co KGaA

Immunwork Inc

Incyte Corp

InflaRx NV

Innovation Pharmaceuticals Inc

InSight Biopharmaceuticals Ltd

Johnson & Johnson

Novartis AG

UCB SA

XBiotech Inc